Approximately half of the world’s population – 3.2 billion people – is at risk of malaria. An estimated 283 million people are infected every year, the disease causes debilitating cycles of pain, fever, coma and even death. According to the World Health Organization, nearly 584 million people died from malaria every year, most of them young children (under 5 years old) in impoverished sub-Saharan Africa.

Established in 1997, the Harvard Malaria Initiative (HMI) is a research and training effort led by world-renowned tropical disease expert Professor Dyann Wirth. Together with collaborators from around the globe, researchers at the Harvard T.H. Chan School of Public Health employ sophisticated laboratory approaches to understand the underlying causes of drug resistance, identify and screen potential new drugs and drug targets, rapidly translate new findings into practical treatments, and train researchers and global public health professionals from the U.S. and malaria endemic regions. In 2012, HMI’s activities were reorganized under the auspices of the university-wide Defeating Malaria: From the Genes to the Globe initiative.

For more information about Harvard University’s Defeating Malaria: From the Genes to the Globe initiative, please visit defeatingmalaria.harvard.edu.